Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiary
辉瑞先付1.5亿美元，收购复星医药子公司小分子GLP-1项目

On Nov. 19, Pfizer CFO Dave Denton said at the Jefferies Global Healthcare Conference that the large pharma was still looking for an oral small molecule for obesity and that it was looking in China.
11月19日，辉瑞首席财务官戴夫•登顿在杰富瑞manbetx app苹果 医疗保健大会上表示，这家大型制药公司仍在寻找用于治疗肥胖的口服小分子药物，而且正在manbetx3.0 进行相关寻找。